RAON.F Stock Overview
A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Race Oncology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.22 |
| 52 Week High | AU$1.22 |
| 52 Week Low | AU$1.22 |
| Beta | 1.74 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -53.08% |
| 5 Year Change | n/a |
| Change since IPO | -60.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| RAON.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | 0.8% |
| 1Y | n/a | 21.7% | 33.4% |
Return vs Industry: Insufficient data to determine how RAON.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how RAON.F performed against the US Market.
Price Volatility
| RAON.F volatility | |
|---|---|
| RAON.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RAON.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RAON.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Daniel Tillett | www.raceoncology.com |
Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors.
Race Oncology Limited Fundamentals Summary
| RAON.F fundamental statistics | |
|---|---|
| Market cap | US$208.90m |
| Earnings (TTM) | -US$9.54m |
| Revenue (TTM) | US$2.76m |
75.6x
P/S Ratio-21.9x
P/E RatioIs RAON.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAON.F income statement (TTM) | |
|---|---|
| Revenue | AU$4.00m |
| Cost of Revenue | AU$2.61m |
| Gross Profit | AU$1.39m |
| Other Expenses | AU$15.21m |
| Earnings | -AU$13.82m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.081 |
| Gross Margin | 34.72% |
| Net Profit Margin | -345.18% |
| Debt/Equity Ratio | 0% |
How did RAON.F perform over the long term?
See historical performance and comparison